FIELD: pharmaceutics.
SUBSTANCE: invention refers to a pharmaceutical composition for controlling or treating a disease or disorder associated with FGF19. Also disclosed is a method for preventing, treating or monitoring a disease or disorder associated with FGF19, as well as use of said pharmaceutical composition.
EFFECT: invention provides effective treatment of diseases associated with FGF19.
118 cl, 13 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| MODIFIED CONSTANT REGION OF ANTIBODY | 2023 |
|
RU2837820C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| MODIFIED ANTIBODY CONSTANT REGION | 2021 |
|
RU2797273C2 |
| RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
| IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
